MedTrace Logo

Adebrelimab Plus S-1 for Resected Cholangiocarcinoma

NCT07561775 · Status: NOT_YET_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2026-05-01

No results posted yet for this study

Summary

The goal of this clinical trial is to learn whether adebrelimab combined with S-1 works as an adjuvant treatment for patients with cholangiocarcinoma after curative surgery. It will also learn about the safety of this treatment. The main questions it aims to answer are:

* Does adebrelimab combined with S-1 reduce the risk of cancer recurrence after surgery?
* What side effects do participants experience when receiving this treatment? All participants in this study will receive adebrelimab combined with S-1. There is no comparison group in this study.

Participants will:

* Receive adebrelimab by intravenous infusion once every 3 weeks for 4 cycles
* Take S-1 by mouth twice daily for 4 weeks, followed by a 2-week rest, for 4 cycles
* Visit the hospital regularly for checkups, laboratory tests, and imaging examinations (CT or MRI)
* Be followed up for safety and survival after completing treatment

Conditions

Interventions

DRUG

Adebrelimab

Adebrelimab will be administered intravenously at a dose of 1200 mg on Day 1 of each 3-week cycle for a total of 4 cycles as adjuvant therapy after curative resection.

DRUG

S-1

S-1 will be administered orally at a dose of 40 mg/m² twice daily on Days 1-28 of each 6-week cycle, followed by a 2-week rest period, for a total of 4 cycles.

Sponsors & Collaborators

  • Xingjun Guo

    lead OTHER

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-04-21
Primary Completion
2028-01-01
Completion
2032-01-01

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07561775 on ClinicalTrials.gov